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Abstract
Background: Microarray studies provide a way of linking variations of phenotypes with their
genetic causations. Constructing predictive models using high dimensional microarray
measurements usually consists of three steps: (1) unsupervised gene screening; (2) supervised gene
screening; and (3) statistical model building. Supervised gene screening based on marginal gene
ranking is commonly used to reduce the number of genes in the model building. Various simple
statistics, such as t-statistic or signal to noise ratio, have been used to rank genes in the supervised
screening. Despite of its extensive usage, statistical study of supervised gene screening remains
scarce. Our study is partly motivated by the differences in gene discovery results caused by using
different supervised gene screening methods.
Results: We investigate concordance and reproducibility of supervised gene screening based on
eight commonly used marginal statistics. Concordance is assessed by the relative fractions of
overlaps between top ranked genes screened using different marginal statistics. We propose a
Bootstrap Reproducibility Index, which measures reproducibility of individual genes under the
supervised screening. Empirical studies are based on four public microarray data. We consider the
cases where the top 20%, 40% and 60% genes are screened.
Conclusion: From a gene discovery point of view, the effect of supervised gene screening based
on different marginal statistics cannot be ignored. Empirical studies show that (1) genes passed
different supervised screenings may be considerably different; (2) concordance may vary, depending
on the underlying data structure and percentage of selected genes; (3) evaluated with the Bootstrap
Reproducibility Index, genes passed supervised screenings are only moderately reproducible; and
(4) concordance cannot be improved by supervised screening based on reproducibility.
Background
Microarray techniques provide a way of monitoring gene
expressions on a large scale. Biomedical experiments have
been designed to discover important genes or gene path-
ways, that are linked with variations of phenotypes. Those
genes can then be used as biomarkers in clinical studies
and to construct predictive models in downstream analy-
sis. Examples of such studies include disease classification
studies in [1-3] and survival analysis in [4,5], among
many others.
Statistical analyses using gene expressions as covariates are
very challenging due to high dimensionality of gene
expression measurements and small sample sizes. Con-
sider for example the Leukemia data [6], which is used as
an example of binary classification in [7]. The data con-
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tains expression measurements of 6817 genes from 72
samples. We refer to [6] for experimental setup. A typical
analysis, as presented in [7], consists of the following
three steps.
1. Data organization and unsupervised gene screening. In
[7], this step consists of thresholding the raw measure-
ments, filtering genes with small variations across all sam-
ples and logarithm transformation. 3571 genes pass the
first stage screening. For other datasets, if severe missing-
ness is present, simple data manipulation, such as filling
in missing values, may also be needed.
2. Supervised gene screening. Genes passed unsupervised
screening are then ranked based on the ratio of their
between-groups and within-groups sum of squares
(referred as B/W hereafter). The 50 top ranked genes are
selected for downstream statistical analysis. We note that
the binary outcome is used in computing the B/W ratio.
3. Predictive model building using the 50 selected genes.
Various statistical methods, including classification tree,
Fisher linear discriminant analysis and nearest neighbor
approach, are used.
Similar three-step approaches have been extensively used.
See for example, classification studies in [6,8,9] and sur-
vival analysis in [4,10], among many others.
We now investigate this three-step procedure in more
details. Steps 1 and 2 carry our gene screening, which is
especially necessary under current "large p, small n" set-
ting. The goal of the screening is three-fold: improving
prediction performance by removing noninformative
genes; providing faster and more cost-effective predictors;
and providing a better understanding of the underlying
causal relationships.
Step 1 is mainly due to technical concerns. For example,
most statistical building methods in step 3 cannot handle
missing data automatically, so we need to either remove
genes with missing values or fill in with sample statistics.
Under certain experimental setup, gene expression meas-
urements above or below certain thresholds are not mean-
ingful, so simple thresholding/flooring may be needed.
Genes with little variations across samples are not likely to
possess any biological functions of interest, so removing
such genes may increase the signal to noise ratio. We note
that in step 1 gene screening and data manipulation,
information on the clinical outcome is not used. We
hence refer it as the unsupervised gene screening.
In this article, step 2 screening is referred as the supervised
gene screening. It differs from the unsupervised screening
in the sense that the clinical outcome is used in gene
screening. A typical supervised screening consists of the
following steps:
(i) Compute a marginal statistic for each individual gene.
This statistic, for example the t-statistic in binary classifi-
cation studies, is constructed using both the expression
measurements and the clinical outcome.
(ii) Rank genes based on their marginal statistics. For this
purpose, although distribution of the marginal statistic
does not need to be known, we do need to know the qual-
itative relationship between magnitude of this statistic
and importance of corresponding gene, for example
whether larger marginal statistics indicate more influen-
tial genes.
(iii) Select the top ranked genes. We postpone discussion
of how many genes need to be selected to the Discussions
section.
In [7], the screening statistic is chosen to be the between-
groups and within-groups sum of squares ratio, and the
binary outcome is used to define the grouping. Although
the distribution and other statistical properties of the B/W
ratio do not need to be known, it is reasonable to say that
genes with larger B/W can better predict the outcome and
hence should be selected. Only the 50 top ranked genes
are used in the statistical model building.
After gene screening in steps 1 and 2, predictive models
can be constructed in step 3. Since the number of genes
passed screening may still be much larger than the sample
size, feature selection through regularization is usually
needed along with estimation. Regularization methods
used include partial least squares [8], LASSO [11], LASSO-
LARS [12] and threshold gradient descent regularization
(TGDR) [13], among many others. With the aforemen-
tioned regularized estimation approaches, only a small
number of representative genes are included in the final
models. The biological implications of those representa-
tive genes are of great scientific interest, and usually war-
rant more detailed investigation.
We note that not all three steps are needed in practical
data analyses. Part of the screening can be omitted. For
example, in the boosting study [14], all genes are used in
the model building. In the above three-step procedure,
step 1 is mainly due to technical concerns and is of less
statistical interest. Step 3 has been intensively studied. See
the aforementioned publications and references therein.
However in previous studies, the supervised gene screen-
ing is usually taken for granted and has not been well
investigated.BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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We first present a small numerical study to show the valid-
ity of the supervised screening. We consider the Colon
and Leukemia data presented in the Results section as
examples. If a gene screening method is valid, it should
have certain reproducibility property. Especially, genes
passed the screening in one subgroup should be similar to
those screened in another independent subgroup. Since
independent validation sets are usually not available, we
consider the following bootstrap based approach.
1. Randomly select 0.632n subjects, where n is the sample
size.
2. Select 20% genes using the chosen screening method.
3. Repeat 1–2 1000 times.
4. For each gene, compute the percentage of times it is
included in the top 20% ranked gene lists.
The percentage computed here is closely related to the
Bootstrap Reproducibility Index proposed below. We
choose statistics 2, 5 and 8 (see the Methods section) as
examples and show the percentage plot in Figure 1. Note
that in Figure 1 we sort the genes based on decreasing per-
centages. We can see from Figure 1 that the percentages are
far from being flat: there are some genes with very high
percentages of being selected, which indicates that the
supervised screening is reasonably reproducible. Studies
with other screening statistics and other datasets show
similar results and are omitted here.
A motivating example
This article is partly motivated by the following example.
Consider the Leukemia data described in [6]. The data
contains expression measurements of 6817 genes for 72
samples, among which 47 are ALL and 25 are AML. The
clinical outcome of interest can be coded as a binary vari-
able with the response equal to 1 if it is AML and 0 other-
Empirical study: validity of supervised gene screening Figure 1
Empirical study: validity of supervised gene screening. The percentages of individual genes being included in the 20% 
top ranked genes computed from 1000 bootstrap samples.
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wise. We employ the same unsupervised screening as in
[7] and 3571 genes pass the unsupervised screening.
For the supervised gene screening, we consider using the
eight different ranking statistics listed in the Methods sec-
tion to select the top 714 (20%) genes. In the statistical
model building, we assume the commonly used logistic
regression models, where the covariates are the 714 genes
passed the unsupervised and supervised gene screenings
and the outcome is the acute leukemia type. Since the
sample size is much smaller than the number of covari-
ates, we use the TGDR, which is capable of simultaneous
estimation and gene selection, for regularized estimation.
Estimation and gene selection using the TGDR has been
studied in [13,15]. The small number genes included in
the final models are identified as important genes, and are
concluded to be associated with the variations of pheno-
types.
Eight possibly different sets of 714 genes passed the gene
screenings are used to construct eight predictive models.
Since the same unsupervised screening, the same logistic
model and the same regularization method are used, dif-
ferences (if any) in the eight final predictive models must
be caused by the differences in the supervised screening.
We show in Table 1 the number of genes included in the
eight models constructed by logistic + TGDR, and their
corresponding overlaps. For example, by using the differ-
ence of mean as the supervised screening statistic and fit-
ting the logistic + TGDR model, 34 out of 714 genes are
included in the final model; while 35 genes are included
if the simple t-statistic is used as the supervised screening
statistic. Only 22 genes are included in both models.
We can see from Table 1 that there exist considerable over-
laps among genes included in the eight final models,
showing moderate concordance of gene discovery results.
However with different supervised screenings, the genes
in the final logistic models may differ by more than 30%.
A total of 66 genes are included in at least one of the eight
final models, where as only 16 are included in all eight.
More detailed gene discovery results are available upon
request. We can conclude that for the Leukemia example,
differences of the predictive models caused by differences
in supervised gene screenings are significant and cannot
be ignored. Similar results are observed for the Colon data
and the Estrogen data.
Microarray studies like the Leukemia example have two
main purposes. The first is to construct predictive models
based on microarray measurements to guide future treat-
ment selection. The second is to discover a small subset of
genes that are accountable for variations of phenotypes.
Identifying such influential genes may lead to better
understanding of human genomics and new directions of
gene therapy. From a scientific point of view, the second
goal is at least as important as the first one. The Leukemia
example shows that the effect of supervised gene screen-
ing, which has considerable effect on gene discovery
results, warrants detailed investigation. Concordance
problem in gene discovery by using different regulariza-
tion methods has been studied. For example, several dif-
ferent gene discovery results have been reported for the
diffuse large-B-cell lymphoma (DLBCL) data. See [16] for
detailed discussions. In this article, we investigate the con-
cordance in supervised gene screening, which has been
neglected previously.
Another challenging aspect of microarray data analysis is
the reproducibility. Empirical studies, for example [17],
show that genes discovery results in one bootstrap sample
are not necessarily reproducible in another one. Repro-
ducibility in gene clustering is recently studied by [18];
Theoretical framework is established in [19,20]; In addi-
tion [21] presents general reproducibility discussions of
feature selection in microarray studies.
The goal of this study is two-fold. Firstly, concordance of
different supervised gene screenings is investigated. Cou-
pled with concordance study of regularized estimation
methods, our study provides further insights into con-
cordance of microarray gene discovery results using differ-
ent statistical approaches. Secondly, reproducibility of
individual genes in supervised screening is considered.
Table 1: Leukemia data: number of genes and overlaps identified by the logistic + TGDR models using genes passed eight different 
supervised screenings.
S t a t i s t i c 12345678
1 3 42 22 53 32 82 42 22 7
2 3 52 82 22 32 22 72 9
3 3 62 52 51 82 73 1
4 3 62 82 42 22 7
5 31 24 22 22
6 33 18 20
7 35 26
8 36BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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The proposed Bootstrap Reproducibility Index provides
more detailed reproducibility assessment than previous
ones. We use empirical studies with four public microar-
ray data to investigate the concordance and reproducibil-
ity. In the supervised screening, we follow the commonly
used three-step procedure: computing (marginal statis-
tics), ranking (based on those statistics) and selecting (top
ranked genes). With slight abuse of terminologies, in the
paper "different supervised screening methods" in fact
means "supervised screening based on different marginal
statistics". The rest of the paper is organized as follows. We
discuss eight commonly used gene screening statistics in
the Methods section and propose the Bootstrap Reproduc-
ibility Index (BRI). Empirical studies using four public
datasets are provided in the Results section. Several related
open questions are raised in the Discussions section. The
article concludes with a short summary.
Results
Data Descriptions
Colon data
In this dataset, expression levels of 40 tumor and 22 nor-
mal colon tissues for 6500 human genes are measured
using the Affymetrix gene chip. In the unsupervised gene
screening, 2000 genes with the highest minimal intensity
across samples are selected by [1]. The data is publicly
available at [22].
Leukemia data
The leukemia dataset is described in [6] and available at
[23]. This dataset comes from a study of gene expression
in two types of acute leukemia: acute lymphoblastic
leukemia (ALL) and acute myeloid leukemia (AML). Gene
expression levels were measured using Affymetrix high
density oligonucleotide arrays containing 6817 human
genes. The data comprise 47 cases of ALL and 25 cases of
AML. We use the same unsupervised screening as in [7]:
(i) thresholding with floor of 100 and ceiling of 16000;
(ii) filtering by excluding genes with max/min≤5 and
max-min≤500, where max and min refer to the maximum
and minimum expression levels of a particular gene across
samples, respectively; and (iii) base 2 logarithm transfor-
mation. 3571 genes pass the unsupervised screening.
Estrogen data
This dataset was first presented in [2,3]. It contains expres-
sion values of 7129 genes from 49 breast tumor samples.
The expression data were obtained using the Affymetrix
gene chip technology and are available at [24]. For the
estrogen data, there are two different response variables
available. The first one describes the status of the estrogen
receptor (ER). 25 samples are ER+, whereas the remaining
24 samples are ER-. The second response variable
describes the lymph nodal (LN) status, which is an indica-
tor for the metastatic spread of the tumor. Here 24 sam-
ples are positive (LN+) and 25 samples are negative (LN-
). We consider the same gene expression data coupled
with the ER and LN outcomes, respectively, and refer
them as Estrogen-ER and Estrogen-LN hereafter. For the
unsupervised screening, we threshold the raw data with a
floor of 100 and a ceiling of 16000. Genes with max/min
≤ 5 and/or max - min ≤ 500 are also excluded. 5146 genes
pass the unsupervised screening. A base 2 logarithmic
transformation is then applied.
Empirical study I: concordance
In the first empirical study, we consider concordance of
gene sets passed the eight different supervised screening
approaches. For the four datasets, 20% (40%, 60%) top
ranked genes pass the supervised screening. We show the
concordance results in Tables 2, 3, 4 (left panels), where
we compute the relative fractions of overlapped genes
between any two screening methods. For example for the
Colon data in Table 2, we first rank the 2000 genes using
the difference of mean (statistic 1) and the t-statistic (sta-
tistic 2) as marginal statistics. Then the top 400 genes
(20%) are selected under each approach separately. 348
genes are identified by both methods, leading to 87%
overlap.
We can observe that there are considerable overlaps
between genes selected under different supervised screen-
ing methods. However, the overlaps are not perfect and
the differences can be as large as 40% (Table 2; Estrogen-
LN and Estrogen-ER). As m/d increases, the relative frac-
tions of overlaps also increase, which suggests higher
degree of concordance. However, even if 60% of genes
pass the screening, the concordance may still be as low as
~75% for the Estrogen-LN data. Similar results are
observed for the Lymphoma data [25], the NCI 60 data
[26] and others. Empirical study I reveals that with com-
monly used supervised screenings, genes selected under
different supervised screenings may be considerably dif-
ferent.
Empirical study II: reproducibility
Reproducibility of the supervised screening can be
assessed with the proposed BRI. As stated in the Back-
ground section, only genes passed the supervised screen-
ing are used in statistical model building. So it is of great
interest to see whether those genes are reproducible.
Although the proposed BRI can measure the reproducibil-
ity of individual genes, we only present summary statistics
(median and inter-quartile range) as the overall measure-
ments of reproducibility for those selected genes. Results
are shown in Table 5.
We can see that in general genes screened by the eight dif-
ferent methods are moderately reproducible. For example
for Colon data when 20% genes are selected in the super-BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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vised screening, the medians of BRI are ~0.7 or 0.8, which
roughly means that for the 400 genes passed supervised
screenings, on average they pass the corresponding super-
vised screenings in 70% to 80% of the bootstrap samples.
Another observation is that as m/d increases, the BRIs also
increase. We can also see that the BRIs for one fixed data
and different screening methods can be slightly different,
which is believed to be caused by the underlying gene dis-
tributions. We note that our reproducibility results are
better than those shown in [17]. This is caused by the
small m/d in [17], where m = 50 and d > 4000.
Empirical study III: concordance of screening based on BRI
In [19], it is suggested that supervised gene screening
should be based on reproducibility, i.e., instead of using
marginal statistics based on all observations, a stability
index should be computed for each gene based on certain
marginal statistics and bootstrap random samples; genes
then can be ranked based on this stability index; top
ranked genes pass the supervised gene screening. Theoret-
ical and empirical studies [19] show that predictive mod-
els can be more powerful if genes are screened based on
reproducibility.
Table 2: Concordance evaluation of 20% top ranked genes identified using the eight different supervised screening statistics. The 
numbers are relative fractions of overlapped genes. Marginal: genes are ranked based on marginal statistics; BRI: genes are ranked 
based on BRI.
Marginal BRI
S t a t i s t i c 1234567812345678
Colon
1 1.00 0.87 0.86 0.93 0.82 0.72 0.86 0.87 1.00 0.86 0.85 0.94 0.82 0.75 0.85 0.86
2 1.00 0.97 0.94 0.88 0.75 0.98 0.99 1.00 0.97 0.93 0.89 0.79 0.98 0.99
3 1.00 0.93 0.90 0.76 0.98 0.97 1.00 0.91 0.90 0.79 0.98 0.97
4 1.00 0.85 0.74 0.93 0.94 1.00 0.86 0.76 0.91 0.92
5 1.00 0.82 0.88 0.88 1.00 0.87 0.88 0.89
6 1.00 0.76 0.75 1.00 0.78 0.78
7 1.00 0.98 1.00 0.97
8 1.00 1.00
Leukemia
1 1.00 0.80 0.79 0.91 0.78 0.71 0.75 0.80 1.00 0.78 0.77 0.90 0.74 0.71 0.72 0.78
2 1.00 0.96 0.89 0.89 0.78 0.90 0.96 1.00 0.96 0.88 0.87 0.81 0.88 0.96
3 1.00 0.88 0.88 0.79 0.91 0.96 1.00 0.87 0.88 0.81 0.89 0.95
4 1.00 0.84 0.75 0.83 0.89 1.00 0.82 0.78 0.81 0.88
5 1.00 0.81 0.85 0.88 1.00 0.84 0.83 0.86
6 1.01 0.75 0.79 1.00 0.76 0.82
7 1.00 0.88 1.00 0.85
8 1.00 1.00
Estrogen-ER
1 1.00 0.81 0.81 0.91 0.75 0.69 0.68 0.82 1.00 0.78 0.78 0.89 0.73 0.70 0.61 0.79
2 1.00 1.00 0.90 0.85 0.75 0.78 0.95 1.00 0.99 0.88 0.85 0.78 0.70 0.94
3 1.00 0.90 0.85 0.75 0.79 0.94 1.00 0.89 0.86 0.78 0.70 0.94
4 1.00 0.82 0.73 0.74 0.90 1.00 0.82 0.75 0.67 0.89
5 1.00 0.80 0.75 0.84 1.00 0.84 0.68 0.84
6 1.00 0.64 0.77 1.00 0.61 0.80
7 1.00 0.73 1.00 0.65
8 1.00 1.00
Estrogen-LN
1 1.00 0.75 0.75 0.89 0.65 0.58 0.64 0.78 1.00 0.72 0.72 0.87 0.64 0.59 0.54 0.74
2 1.00 1.00 0.86 0.74 0.58 0.84 0.91 1.00 1.00 0.85 0.78 0.63 0.70 0.91
3 1.00 0.86 0.74 0.58 0.84 0.90 1.00 0.85 0.78 0.63 0.70 0.91
4 1.00 0.72 0.60 0.74 0.87 1.00 0.72 0.61 0.63 0.85
5 1.00 0.67 0.69 0.73 1.00 0.71 0.61 0.76
6 1.00 0.50 0.61 1.00 0.46 0.66
7 1.00 0.75 1.00 0.61
8 1.00 1.00BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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The focus of our study is the concordance of different
supervised screening methods, instead of the predictive
model building. However, it is of interest to see if state-
ment in [19] can be extended to supervised screening, i.e,
if concordance of supervised screening can be improved if
genes are screened based on reproducibility measure-
ment. We consider the following empirical study. For each
gene screening statistic, we (1) compute the BRIs for all
genes based on bootstrap samples; (2) rank the genes
based on the BRIs; (3) identify the genes with the highest
BRIs; and (4) compute the concordance between gene sets
identified in (3). Compared with empirical study I, the
same eight marginal statistics are used. However, in
empirical study I, we compute the marginal statistic once
for each gene, and the computation is based on all obser-
vations. In empirical study III, the marginal statistics are
computed multiple times: once for each bootstrap sample.
The statistic used to rank the genes is the BRI.
We show in Tables 2, 3, 4 (right panels) the concordance
results if genes are screened based on the BRI. We can see
that the results are very similar to those shown in the left
panels. We do not observe significant improvement of
concordance by using the BRI for screening. This observa-
Table 3: Concordance evaluation of 40% top ranked genes identified using the eight different supervised screening statistics. The 
numbers are relative fractions of overlapped genes. Marginal: genes are ranked based on marginal statistics; BRI: genes are ranked 
based on BRI.
Marginal BRI
S t a t i s t i c 1234567812345678
Colon
1 1.00 0.94 0.93 0.97 0.88 0.93 0.78 0.94 1.00 0.93 0.93 0.96 0.88 0.93 0.79 0.93
2 1.00 0.99 0.97 0.89 0.79 1.00 0.99 1.00 0.99 0.96 0.90 0.99 0.81 1.00
3 1.00 0.96 0.89 0.79 0.99 0.99 1.00 0.96 0.90 0.99 0.81 0.99
4 1.00 0.89 0.78 0.97 0.96 1.00 0.90 0.96 0.80 0.97
5 1.00 0.85 0.89 0.89 1.00 0.90 0.87 0.90
6 1.00 0.79 0.79 1.00 0.81 0.99
7 1.00 0.99 1.00 0.81
8 1.00 1.00
Leukemia
1 1.00 0.88 0.88 0.94 0.84 0.78 0.88 0.87 1.00 0.87 0.87 0.94 0.83 0.85 0.77 0.87
2 1.00 0.98 0.94 0.89 0.80 0.98 0.97 1.00 0.98 0.93 0.89 0.95 0.80 0.98
3 1.00 0.94 0.90 0.80 0.97 0.97 1.00 0.93 0.90 0.96 0.81 0.97
4 1.00 0.88 0.79 0.94 0.92 1.00 0.87 0.91 0.79 0.93
5 1.00 0.85 0.89 0.89 1.00 0.88 0.86 0.89
6 1.00 0.80 0.78 1.00 0.79 0.93
7 1.00 0.95 1.00 0.81
8 1.00 1.00
Estrogen-ER
1 1.00 0.87 0.87 0.94 0.80 0.77 0.89 0.83 1.00 0.87 0.87 0.94 0.81 0.80 0.76 0.87
2 1.00 1.00 0.93 0.85 0.76 0.93 0.93 1.00 1.00 0.93 0.86 0.87 0.79 0.95
3 1.00 0.93 0.85 0.76 0.93 0.93 1.00 0.93 0.86 0.87 0.78 0.96
4 1.00 0.83 0.77 0.93 0.88 1.00 0.84 0.85 0.78 0.92
5 1.00 0.82 0.82 0.83 1.00 0.78 0.85 0.86
6 1.00 0.79 0.72 1.00 0.71 0.82
7 1.00 0.86 1.00 0.80
8 1.00 1.00
Estrogen-LN
1 1.00 0.85 0.85 0.93 0.75 0.69 0.87 0.84 1.00 0.82 0.82 0.90 0.74 0.77 0.66 0.82
2 1.00 1.00 0.92 0.81 0.66 0.92 0.97 1.00 1.00 0.90 0.81 0.86 0.68 0.96
3 1.00 0.91 0.80 0.65 0.92 0.98 1.00 0.90 0.81 0.86 0.68 0.96
4 1.00 0.78 0.68 0.92 0.90 1.00 0.78 0.86 0.67 0.90
5 1.00 0.74 0.77 0.80 1.00 0.73 0.77 0.81
6 1.00 0.69 0.64 1.00 0.60 0.83
7 1.00 0.90 1.00 0.70
8 1.00 1.00BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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tion can be partly explained by the fact that genes screened
in empirical studies I and III are almost identical. For
example for the Colon data when 20% genes are selected
(Table 2), about 95% of genes passed the screening in
empirical study I are also selected in empirical study III.
Similar high overlaps are observed for other datasets.
Although further theoretical investigation is still needed,
our empirical study leads to the conclusion that super-
vised screening based on reproducibility measurement
cannot improve the concordance.
Discussion
Remark: how to choose supervised screening methods
Empirical studies above show that the effect of supervised
screening on predictive model building is not ignorable.
See Table 1 for example. Our study focuses on concord-
ance and reproducibility measurements. However, we
note that our study does not lead to any recommendations
on how to choose the supervised screening methods. Such
a question still remains open. Theoretically speaking,
validity (in terms of consistent gene selection) of super-
vised gene screening depends on the unknown underlying
model and data distribution. For practical data analysis,
Table 4: Concordance evaluation of 60% top ranked genes identified using the eight different supervised screening statistics. The 
numbers are relative fractions of overlapped genes. Marginal: genes are ranked based on marginal statistics; BRI: genes are ranked 
based on BRI.
Marginal BRI
S t a t i s t i c 1234567812345678
Colon
1 1.00 0.96 0.96 0.98 0.88 0.79 0.96 0.96 1.00 0.94 0.94 0.97 0.88 0.94 0.79 0.94
2 1.00 0.99 0.98 0.89 0.80 1.00 1.00 1.00 0.99 0.97 0.90 1.00 0.80 1.00
3 1.00 0.97 0.89 0.80 0.99 0.99 1.00 0.97 0.90 0.99 0.80 0.99
4 1.00 0.89 0.80 0.98 0.98 1.00 0.89 0.97 0.80 0.97
5 1.00 0.87 0.89 0.89 1.00 0.90 0.86 0.89
6 1.00 0.80 0.80 1.00 0.80 1.00
7 1.00 1.00 1.00 0.80
8 1.00 1.00
Leukemia
1 1.00 0.94 0.94 0.97 0.89 0.82 0.94 0.94 1.00 0.91 0.91 0.96 0.87 0.91 0.79 0.91
2 1.00 0.99 0.97 0.91 0.82 0.99 0.99 1.00 0.99 0.95 0.91 0.98 0.81 0.99
3 1.00 0.97 0.91 0.81 0.98 0.99 1.00 0.95 0.92 0.98 0.81 0.99
4 1.00 0.90 0.82 0.96 0.96 1.00 0.90 0.95 0.80 0.95
5 1.00 0.86 0.90 0.91 1.00 0.90 0.85 0.91
6 1.00 0.82 0.81 1.00 0.80 0.97
7 1.00 0.98 1.00 0.81
8 1.00 1.00
Estrogen-ER
1 1.00 0.92 0.92 0.96 0.85 0.80 0.93 0.92 1.00 0.89 0.89 0.95 0.83 0.89 0.77 0.90
2 1.00 1.00 0.96 0.87 0.78 0.94 0.99 1.00 1.00 0.92 0.87 0.91 0.79 0.98
3 1.00 0.96 0.87 0.78 0.94 0.99 1.00 0.92 0.87 0.91 0.79 0.98
4 1.00 0.86 0.79 0.95 0.95 1.00 0.84 0.94 0.77 0.93
5 1.00 0.83 0.84 0.87 1.00 0.82 0.84 0.86
6 1.00 0.81 0.78 1.00 0.74 0.91
7 1.00 0.94 1.00 0.79
8 1.00 1.00
Estrogen-LN
1 1.00 0.92 0.92 0.96 0.81 0.74 0.91 0.92 1.00 0.85 0.85 0.93 0.77 0.86 0.69 0.85
2 1.00 1.00 0.97 0.83 0.73 0.96 1.00 1.00 1.00 0.89 0.83 0.91 0.72 0.97
3 1.00 0.97 0.83 0.73 0.96 1.00 1.00 0.89 0.84 0.91 0.72 0.97
4 1.00 0.83 0.73 0.94 0.96 1.00 0.78 0.93 0.68 0.90
5 1.00 0.79 0.81 0.83 1.00 0.78 0.78 0.82
6 1.00 0.75 0.73 1.00 0.67 0.92
7 1.00 0.73 1.00 0.71
8 1.00 1.00BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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universally optimal supervised screening method is not
expected to exist.
Although screening based on marginal statistics has been
extensively used, recent studies [27,28] show that super-
vised gene screening should also consider the correlation
structures among genes, and marginal methods may not
be optimal. In addition, [21] shows that a gene that is
'useless" by itself can be helpful in the joint models.
Empirical study of adaptive selection of supervised screen-
ing method based on reproducibility will be studied in a
later article.
Remark: how many genes should be selected
Our empirical studies show that as m/d increases, the con-
cordance and reproducibility measurements of all eight
screening methods increase. So from concordance and
reproducibility point of view, larger m is preferred. How-
ever with larger m, more genes, including noisy genes,
pass the supervised screening. This contradicts the noise-
removal and model-reduction purposes of the supervised
screening. The predictive models are expected to be less
reliable, when more genes are used in the model building.
So the number of genes passed supervised screening
should balance between the concordance and reproduci-
bility requirement and the predictive model building.
Theoretical studies [29] show that the number of genes
can at most be in the order of exp(n) for a given sample
size n. Such results provide an asymptotic guideline for
determining the number of genes. However, to our best
knowledge, there is no theoretical or empirical studies tar-
geting the optimal choice of m for practical datasets with
small n.
Remark: effect of unsupervised screening
In our empirical study, unsupervised screening is carried
out for all four datasets. Our unsupervised screening fol-
lows [1] for Colon data and [7] for Leukemia and Estrogen
data. It is believed that different unsupervised screenings
will affect supervised screening and predictive model
building results. Unfortunately, as for supervised screen-
ing, there has not been enough study of unsupervised
screening. Previous used unsupervised screenings are case-
Table 5: Summary of BRI of genes passed supervised screenings: median and inter-quartile range.
Statistic Colon Leukemia Estrogen-ER Estrogen-LN
m/d = 20%
1 0.82 [0.62, 0.96] 0.84 [0.63, 0.98] 0.77 [0.55, 0.96] 0.59 [0.46, 0.75]
2 0.77 [0.57, 0.95] 0.75 [0.54, 0.94] 0.73 [0.51, 0.94] 0.55 [0.43, 0.72]
3 0.77 [0.58, 0.95] 0.75 [0.55, 0.94] 0.73 [0.51, 0.94] 0.55 [0.43, 0.72]
4 0.78 [0.60, 0.96] 0.79 [0.59, 0.96] 0.76 [0.53, 0.95] 0.57 [0.45, 0.74]
5 0.76 [0.56, 0.94] 0.75 [0.54, 0.93] 0.72 [0.53, 0.94] 0.55 [0.43, 0.73]
6 0.68 [0.50, 0.88] 0.72 [0.54, 0.91] 0.72 [0.53, 0.92] 0.57 [0.46, 0.73]
7 0.77 [0.57, 0.94] 0.75 [0.54, 0.94] 0.72 [0.51, 0.93] 0.59 [0.43, 0.77]
8 0.76 [0.58, 0.94] 0.76 [0.56, 0.94] 0.74 [0.52, 0.95] 0.56 [0.44, 0.73]
m/d = 40%
1 0.84 [0.64, 0.97] 0.84 [0.61, 0.98] 0.79 [0.59, 0.96] 0.66 [0.52, 0.83]
2 0.83 [0.62, 0.97] 0.81 [0.60, 0.97] 0.77 [0.56, 0.97] 0.64 [0.50, 0.82]
3 0.83 [0.62, 0.97] 0.81 [0.59, 0.97] 0.77 [0.57, 0.97] 0.64 [0.50, 0.82]
4 0.83 [0.64, 0.97] 0.83 [0.61, 0.98] 0.78 [0.57, 0.96] 0.65 [0.51, 0.82]
5 0.81 [0.60, 0.96] 0.81 [0.60, 0.97] 0.79 [0.60, 0.96] 0.65 [0.51, 0.81]
6 0.83 [0.62, 0.96] 0.82 [0.60, 0.97] 0.78 [0.58, 0.96] 0.67 [0.51, 0.85]
7 0.76 [0.56, 0.93] 0.78 [0.59, 0.95] 0.78 [0.60, 0.95] 0.70 [0.58, 0.84]
8 0.83 [0.62, 0.96] 0.81 [0.59, 0.97] 0.78 [0.57, 0.96] 0.64 [0.51, 0.82]
m/d = 60%
1 0.86 [0.65, 0.97] 0.86 [0.66, 0.99] 0.82 [0.64, 0.97] 0.73 [0.61, 0.89]
2 0.85 [0.65, 0.97] 0.85 [0.64, 0.98] 0.83 [0.63, 0.98] 0.73 [0.59, 0.89]
3 0.85 [0.64, 0.97] 0.85 [0.64, 0.99] 0.83 [0.63, 0.98] 0.73 [0.59, 0.89]
4 0.85 [0.65, 0.97] 0.85 [0.65, 0.99] 0.82 [0.64, 0.97] 0.73 [0.61, 0.88]
5 0.82 [0.62, 0.97] 0.85 [0.64, 0.98] 0.84 [0.64, 0.98] 0.73 [0.59, 0.88]
6 0.85 [0.65, 0.97] 0.85 [0.65, 0.99] 0.84 [0.65, 0.97] 0.75 [0.60, 0.90]
7 0.80 [0.63, 0.96] 0.85 [0.68, 0.98] 0.86 [0.71, 0.98] 0.83 [0.71, 0.93]
8 0.85 [0.65, 0.97] 0.85 [0.64, 0.98] 0.82 [0.63, 0.97] 0.73 [0.60, 0.89]BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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specific and usually depend on the actual experimental
settings. Without accessing the experimental setup and
interacting with the original researchers, we are not able to
provide an honest assessment of the unsupervised screen-
ing in our study. We refer to aforementioned publications
for rationale of the specific unsupervised screening.
Remark: connections with detection of differentially 
expressed genes
In simple microarray settings such as the Apo AI study in
[30], the goal is to detect genes differentially expressed. For
binary classification problem such as the Colon data, we
can also lower our goal from statistical model building to
detection of genes that are differentially expressed
between diseased and healthy subjects. If so, then all the
eight statistics discussed in last section can be used to rank
and detect differentially expressed genes. The reproduci-
bility of such studies has been investigated in [31] and ref-
erences therein.
Although in our study, supervised screening and detection
of differential genes are nearly identical, in general they
can be significantly different in the following sense.
Firstly, detection of differential genes is usually under the
simple setting with two sub-populations. The two sub-
populations may come from different experimental set-
tings and it is not always reasonable to assume statistical
models linking gene expressions with the outcome, i.e,
the causality does not necessarily exist. Supervised screen-
ing is used before a statistical model can be built. It is
employed in much more general settings, for example in
survival analysis or longitudinal studies. Secondly, super-
vised screening can be based on reproducibility. This has
been proposed and proved to function. However, it is not
clear whether reproducibility measurement can be used in
differential gene detection. Thirdly, when defining differ-
entially expressed genes, certain statistical properties of
the marginal statistics need to be known. For example for
genes not differentially expressed, the p-values for t-statis-
tics are uniformly distributed. With supervised screening,
we only need to rank the genes and the top ranked are
selected. Hence only minimum properties of the ranking
statistic need to be known. Fourthly, in detection of differ-
ential genes, the correlation structure of the genes has sig-
nificant effect on the distribution of marginal statistics
and hence detection results. See [32] for discussions. In
the supervised screening, the distribution of the ranking
statistics is of less interest: only the relative ranking of
those (possibly correlated) statistics is used. So as long as
the marginal distributions are fixed, the correlation struc-
tures among genes have no effect on the supervised
screening.
Conclusion
In microarray studies, supervised gene screening is usually
carried out before statistical model building. In this arti-
cle, we investigate the concordance and reproducibility of
supervised screening via empirical studies. Our study
leads to the following conclusions: (1) effect of supervised
screening on predictive model building and gene discov-
ery should not be ignored. Explanations of gene discovery
results should be with extra cautions, if supervised screen-
ing is used; (2) genes passed different supervised screen-
ings can be considerably different. The concordance
depends on the screening statistics, underlying data struc-
tures and number of genes selected; (3) as measured by
the BRI, genes passed supervised screenings are only mod-
erately reproducible and the reproducibility also depends
on the number of genes selected; and (4) supervised
screening based on reproducibility cannot improve con-
cordance.
The goal of this study is to provide empirical evidence for
the concordance and reproducibility problems in super-
vised gene screening, which has not been detailed studied
previously. Several related questions still remain open
and are listed in last section. Although of great impor-
tance, they are beyond the scope of this article.
Methods
Supervised screening statistics in binary classification
Clinical outcomes being considered in microarray studies
include categorical outcome (presence or absence of dis-
ease; different stages of disease), censored survival out-
come (occurrence time of disease related event) and
continuous outcome (value of disease biomarker), among
others. Although unsupervised and supervised gene
screenings are needed for analyses of all aforementioned
outcomes, we first focus on binary outcome because of its
popularity and simplicity.
Denote the outcome of interest as Y, where subjects with
Y  = 1 are referred as diseased and otherwise healthy.
Denote X as the length d vector of gene expressions. In
addition, denote XD and XH as gene expressions for dis-
eased and healthy subjects, respectively. We assume there
exist n i.i.d observations with nD diseased and nH healthy
subjects and nD + nH = n. For gene j = 1,...,d, denote 
and   as the sample means of gene expressions for dis-
eased and healthy subjects, respectively. Denote   and
 as the corresponding sample standard deviations.
Denote Tj, j = 1...,d as the marginal statistics that are used
to rank and screen genes. The following ranking statistics
have been extensively used in previous studies.
Xj
D
Xj
H
ˆ σ j
D
ˆ σ j
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1. Difference of mean. The statistic for the jth gene is
defined as Tj = |  -  |. Top ranked genes have large
Tj. Using the difference of mean as ranking criteria has
been investigated in [20] and references therein.
2. Simple t-statistic. For each gene, we first compute the
pooled variance estimate as   = {(nD - 1)  + (nH -
1) }/(nD + nH - 2). The t-statistic is defined as Tj = (
- )/ p. A larger absolute value of Tj leads to higher
rank. For binary classification, supervised screening using
t-statistic is equivalent to using the correlation coefficient
[21] and the B/W ratio [7]. The correlation coefficient can
be used when the outcome is a continuously distributed
variable. In that case, the simple t-statistic cannot be
directly employed. When the outcome is categorical with
more than two levels, the B/W can be directly used
whereas the t-statistic can be modified to an F-type statis-
tic.
3. Signal to noise ratio [33]. The statistic is defined as
. Interestingly, using the
signal to noise ratio for binary classification yields the
same ranking as using the binormal AUC [9], which is the
ranking criteria from the binormal ROC method. We note
that both the signal to noise ratio and the binormal AUC
have been extensively used and can be extended to much
more general cases.
4. SAM (Significance Analysis of Microarray) with fudge
factor. Ranking based on the SAM statistic has been exten-
sively used. For discussion, see [34,35]. The SAM statistic
is modified from the simple t-statistic and defined as Tj =
(  -  )/( p + f), where f is the positive fudge factor.
In our study, we simply set f = median( p). Data-adaptive
fudge factor selection has been discussed in [35].
5. Wilcoxon rank-sum statistic. For gene j, the expression
levels are ranked first. Denote   as the sum of ranks for
the expression levels of diseased subjects. The Wilcoxon
statistic is computed as  .
6. Kolmogorov-Smirnov statistic. For gene j, nonparamet-
ric estimates of the gene expression distribution functions
for diseased and healthy subjects are separately computed.
The KS statistic is defined as the maximum distance
between the two estimated distributions.
7. Estimated coefficient from marginal logistic regression.
We first normalize all genes to have unit variances. The
marginal logistic regression for the jth  gene assumes
logit(E(Y = 1|Xj)) = αj + βjXj, with unknown intercept αj
and regression coefficient βj. Tj is set as the absolute value
of the maximum likelihood estimate of βj.
8. P-value from marginal logistic regression. Tj is set as the
p-value corresponding to the estimate of βj from the logis-
tic model in 7.
Statistics 1–4 are related to the simple t-statistic, which is
a parametric statistic based on the normal or asymptotic
normal distribution assumption. The difference of mean
can be obtained from t-statistic by assuming equal vari-
ances across genes. If we ignore the difference between the
number of diseased and healthy subjects, t-statistic can be
simplified as the signal to noise ratio. The SAM statistic is
a simple modification of the t-statistic, mainly due to the
concern that extremely large t-statistic may be caused by
small sample size and hence small variance estimate. The
fudge factor is supposed to pull the extreme variance esti-
mates towards their average. The Wilcoxon and Kol-
mogorov-Smirnov statistics are nonparametric. They rely
on less assumptions on the marginal distributions than
the t-statistic. However, the drawback is that nonparamet-
ric statistics may not be powerful enough, especially for
microarray data when the sample size is very small. Statis-
tics 7 and 8 are based on marginal logistic models, which
are the most commonly assumed robust models in binary
classification. Such model based methods are less com-
mon in classification study, but very popular in survival
analysis [4] and linear regressions.
Loosely speaking, all the eight supervised screening statis-
tics are designed to test the marginal hypothesis H0j:
E()  =  E( ). If we assume that the gene expressions
for the diseased and healthy subjects are both normally
distributed with the same variance but different means,
then for fixed d and n → ∞, all the eight screening meth-
ods can consistently identify differentially expressed genes
and hence properly screen genes. Thus the eight different
screening methods are valid and the ranking/screening
results should be concordant asymptotically. However,
for gene expression data with small sample sizes, the nor-
mal distribution assumption may not be satisfied. In
addition, as shown in [29], even when the normal distri-
bution assumption is satisfied, finite sample perform-
Xj
D Xj
H
ˆ σp
2 ˆ σ j
D2
ˆ σ j
H2 Xj
D
Xj
H ˆ σ
TXX jj
D
j
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j
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j
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ances of different screening statistics may still be
considerably different.
Concordance measurement
We consider the following concordance measurement for
gene sets passed different supervised screenings. Assume
that we select m  top ranked genes based on different
supervised screening statistics. For any two sets, concord-
ance is measured by the percentage of overlap. Beyond
depending on the underlying data structures and the rank-
ing statistics used, the proposed concordance measure-
ment also depends on the ratio of m/d, as shown in the
Results section. For example in the extreme case of m/d ~
1, almost all genes are selected and concordance is close
to 1 for any screening methods. In our empirical studies,
we consider three different m/d ratios.
An alternative concordance measure is the preservation
degree of ranking based on two different ranking statistics.
Studies using such concordance measurement can be
found in [31]. This is the proper measure of concordance
if ranking of the selected genes is of interest, for example
in study of detecting differentially expressed genes where
higher ranked genes warrant more detailed studies. In
supervised gene screening, the purpose of ranking and
screening is to provide a set of working genes for down-
stream model building. So the relative ranking of the
screened genes is of less interest. For this reason, the pro-
posed concordance measure is proper.
Bootstrap Reproducibility Index
Genes that are more reproducible carry stronger and more
stable information of the causal relationship. In [19], it is
proposed that gene ranking and screening can be based on
reproducibility, where reproducibility is an overall meas-
urement evaluated based on the number of overlapped
genes among bootstrap samples. Although having sound
theoretical basis, such reproducibility measurement
focuses on the overall reproducibility of ranking/grouping
methods instead of the reproducibility of individual
genes.
Motivated by aforementioned studies, we consider the fol-
lowing Bootstrap Reproducibility Index (BRI), which
shares the same spirits as the occurrence index measure-
ment proposed in [36]. The BRI is computed as follows.
1. Randomly sample n1 subjects from the n observations
without replacement. In our study, we propose using n1 ~
0.632 × n.
2. For each bootstrap sample and a fixed gene screening
method, compute the marginal statistics   for gene j =
1,..., d. Select the m top ranked genes.
3. Repeat steps 2 and 3 B = 1000 times.
4. For gene j, compute Oj: the number of times this gene
is included in the m top ranked genes out of the B boot-
strap samples.
5. The BRI for gene j under the chosen screening statistic
is defined as BRIj = Oj/B.
We generate random bootstrap samples in step 1. In the
ideal case, reproducibility should be evaluated using inde-
pendent samples. Since such samples usually do not exist,
we create random samples using bootstrap. The "0.632"
bootstrap without replacement is investigated in [37]. The
rationale is that if we sample n subjects with replacement,
then the expected number of unique observations is
0.632n. Bootstrapping and screening are iterated in step 3.
The BRI computed in step 5 is defined as the relative frac-
tion of occurrence.
For a specific subset of genes, we can compute simple
summary statistics, for example mean or median of the
individual BRIs, as the overall reproducibility measure-
ment. Especially, since genes passed the supervised screen-
ing will be used in downstream model building,
reproducibility of those genes are of special interest. In
our empirical studies, we compute the median and inter-
quartile range of BRI for those genes.
The proposed BRI is closely related to the reproducibility
measurement in [19]. If the reproducibility measurement
in [19] is high, then the rank of genes is preserved across
bootstrap samples, which means that a subset of genes
rank high in most bootstrap samples. Since those genes
will pass the supervised screening in most bootstrap sam-
ples, they also have large BRIs.
Supervised screening in survival analysis and linear 
regression
Supervised gene screening is also needed for analysis of
survival type and continuous outcomes. In such studies,
previously proposed supervised screenings are often
model based. For example in [4], marginal Cox models
using the survival outcome and individual gene expres-
sions as covariates are first fit. Supervised screening statis-
tic is chosen as the p-value from the marginal Cox model.
For survival type outcome, an alternative approach is to
consider each time point separately. Then the event indi-
cator, which is binary, can be used as the outcome. The
screening statistics for binary outcome listed above can
then be adopted. One example is the time-dependent
ROC approach [38], which is extended from the ROC
method for binary classification. The time-integrated AUC
can be used as the screening statistic. Tj
∗BMC Bioinformatics 2006, 7:537 http://www.biomedcentral.com/1471-2105/7/537
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For continuous outcomes, marginal linear models can be
fit, and the ranking statistic can be chosen as the p-value
or the actual value of the regression coefficient. Correla-
tion coefficient, which is used in binary classification, is
also applicable for data with continuous outcomes.
Another alternative approach is to dichotomize continu-
ous outcomes and create categorical variables. Then
screening statistics for binary classification can be
adopted. We postpone investigation of supervised screen-
ing with survival and continuous outcomes to a future
study.
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